Scholar Rock (SRRK) Stock Price, News & Analysis

Company Overview

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA). In addition to its SMA candidate, Scholar Rock is advancing therapeutic candidates that inhibit other members of the transforming growth factor-beta (TGF-β) superfamily. These programs address indications such as fibrotic diseases, immuno-oncology and rare genetic bone disorders, with several assets in preclinical or early clinical development.

Scholar Rock’s proprietary platform combines structural biology, protein engineering and translational pharmacology to identify and optimize molecules that bind selectively to growth factor precursors or associated regulatory proteins. By focusing on the latency and activation mechanisms of signaling proteins, the company seeks to fine-tune growth factor activity, reduce off-target effects and expand the range of treatable conditions. Collaboration with academic institutions and strategic partnerships supports the advancement of its pipeline and fosters translational science.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Scholar Rock is led by President and CEO Paul J. Rubin. The company conducts clinical trials and research collaborations in North America and engages with global regulators and investigators to advance its programs. Scholar Rock’s executive team and board include leaders with experience in biopharmaceutical development, clinical strategy and regulatory affairs, underscoring its commitment to delivering innovative therapies to patients with high-unmet-need conditions.

Key Stats

• Today's Range: $47.59 to $48.78
• 50-Day Range: $39.79 to $51.28
• 52-Week Range: $27.07 to $51.63
• Volume: 852,226 shs
• Average Volume: 1.25 million shs
• Market Capitalization: $5.77 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $56.00
• Consensus Rating: Buy

Scholar Rock Stock Analysis - MarketRank™

Scholar Rock scored higher than 55% of companies evaluated by MarketBeat, and ranked 438th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Scholar Rock has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 strong buy ratings, 12 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Scholar Rock has a consensus price target of $56.00, representing about 16.4% upside from its current price of $48.13.

Amount of Analyst Coverage

Scholar Rock has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scholar Rock are expected to grow in the coming year, from ($3.18) to ($2.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scholar Rock is -13.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scholar Rock is -13.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scholar Rock has a P/B Ratio of 20.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.35% of the float of Scholar Rock has been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 10.78, which indicates bearish sentiment.

Change versus previous month

Short interest in Scholar Rock has recently increased by 0.62%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scholar Rock does not currently pay a dividend.

Dividend Growth

Scholar Rock does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.59

News Sentiment

Scholar Rock has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Scholar Rock this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for SRRK on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.

MarketBeat Follows

5 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,546,591.00 in company stock.

Percentage Held by Insiders

13.30% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 5/22/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• Next Earnings (Estimated): 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRRK
• CIK: 1727196
• Web: www.scholarrock.com
• Phone: (857) 259-3860
• Fax: 866-493-4935
• Employees: 140
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Scholar Rock: $56.00
• High Price Target: $70.00
• Low Price Target: $42.00
• Potential Upside/Downside: +16.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.17
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$377.94 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -163.52%
• Return on Assets: -96.67%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 8.64
• Quick Ratio: 8.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.30 per share
• Price / Book: 20.93

Miscellaneous

• Outstanding Shares: 119,830,000
• Free Float: 103,891,000
• Market Cap: $5.77 billion
• Optionable: Optionable
• Beta: 0.70